Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapyKendrick Yim, Mark A. Preston, Affan Zafar et al.|Urologic Oncology Seminars and Original Investigations|2023Cited by 31
MP54-14 SEQUENTIAL INTRAVESICAL GEMCITABINE/DOCETAXEL PROVIDES A DURABLE REMISSION IN RECURRENT HIGH RISK NMIBC FOLLOWING BCG THERAPYKendrick Yim, Mark A. Preston, Kevin Melnick et al.|The Journal of Urology|2022Cited by 1